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Garuda 5 (khyung lnga): Ecologies of Potency and the 
Poison-Medicine Spectrum of Sowa Rigpa’s Renowned 
‘Black Aconite’ Formula
This article focuses on ethnographic 
work conducted at the Men-Tsee-Khang 
(Dharamsala, India) on Garuda 5 (khyung lnga), a 
commonly prescribed Tibetan medical formula. 
This medicine’s efficacy as a painkiller and 
activity against infection and inflammation 
is largely due to a particularly powerful plant, 
known as ‘virulent poison’ (btsan dug) as 
well as ‘the great medicine’ (sman chen), and 
identified as a subset of Aconitum species. Its 
effects, however, are potentially dangerous or 
even deadly. How can these poisonous plants 
be used in medicine and, conversely, when 
does a medicine become a poison? How can 
ostensibly the same substance be both harmful 
and helpful? The explanation requires a more 
nuanced picture than mere dose dependency. 
Attending to the broader ‘ecologies of 
potency’ in which these substances are locally 
enmeshed, in line with Sienna Craig’s Efficacy 
and the Social Ecologies of Tibetan Medicine 
(2012), provides fertile ground to better 
understand the effects of Garuda 5 and how 
potency is developed and directed in practice. 
I aim to unpack the spectrum between sman 
(medicine) and dug (poison) in Sowa Rigpa by 
elucidating some of the multiple dimensions 
which determine the activity of Garuda 5 
as it is formulated and prescribed in India. I 
thus embrace the full spectrum of potency— 
the ‘good’ and the ‘bad,’ the ‘wanted’ and the 
‘unwanted’—without presuming the universal 
validity of biomedical notions of toxicity and 
side effects.
Keywords: poison-medicine dichotomy, herbal toxicity, side 
effects, aconite, Sowa Rigpa (Tibetan medicine).
Jan M. A. van der Valk
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Introduction
There was once a kingdom in eastern India whose 
inhabitants were bothered by lymph (chu ser) dis-
orders and diseases caused by klu (subterranean or 
aquatic elemental spirits) and by microorganisms; 
it was possibly leprosy. Not knowing where to turn, 
the king and his subjects took refuge in the Three 
Jewels (Buddha, dharma, and sangha). As a result of 
this observance, Garuda (a mythical bird) mani-
fested to help the kingdom and cleared away the 
obstacles faced by the people. When he was about 
to die, Garuda offered his body as medicine so that 
the people could continue to enjoy his blessings in 
the form of pills to be taken internally or worn as 
amulets. Garuda further promised that when the 
materials of his body were exhausted, his blessings 
would continue in the form of drugs. Thus it is said 
that a ru ra (chebulic myrobalan) symbolizes Garu-
da’s flesh, ru rta (costus) symbolizes Garuda’s bones, 
shu dag nag po (sweet flag) symbolizes Garuda’s 
muscles, gla rtsi (musk) symbolizes Garuda’s blood, 
and bong nga nag po (dark-blue aconite) symbolizes 
Garuda’s heart. (Gyatso and Hakim 2010: 317)
Gyatso and Hakim (2010) present a convenient summary 
of a myth narrating the origins of the medicine named 
‘Garuda 5’ (khyung lnga), in which its five ingredients 
correspond to the Garuda’s1 body parts. A dark-colored, 
‘black aconite’ (bong nga nag po, or bongnak) is identified 
as the heart of this mythical bird.2 The efficacy of this 
commonly prescribed formula against acute afflictions 
such as pain, infection and inflammation is in large part 
due to this ‘heart.’ This particularly powerful plant that 
is also named menchen (sman chen), ‘the great medicine,’ 
as well as tsenduk (btsan dug), ‘virulent poison,’ has been 
equated with a subset of Aconitum species by contemporary 
botanists and amchi (am chi, Sowa Rigpa practitioners; 
van der Valk 2017: 52-54).3 Its strong potency, however, is 
potentially dangerous or even deadly. How can poisonous 
plants be used in medicine, or conversely: when does a 
medicine become a poison? How can ostensibly the same 
substance be both harmful and helpful? These questions 
beg a more nuanced explanation than mere dose-depen-
dency. Based on ethnographic observations and interviews 
with amchi from the Men-Tsee-Khang (the Tibetan Medical 
and Astrological Institute re-established in exile in 1961)4 
in Dharamsala, India, I aim to show that the activity of 
Garuda 5 and of potent substances in general is better 
understood as enmeshed in local ecologies of potency  
that do not presuppose a separation of ‘wanted’ and 
‘unwanted’ effects.
‘The dose makes the poison’5 is a famous adage formulated 
by the sixteenth-century Renaissance scholar Paracelsus 
(1493-1541), whose ideas lie at the foundation of modern 
toxicology (Klaassen 2013: 5): (1) experimentation with 
single chemical entities (a ‘toxicon,’ as opposed to 
mixtures) is essential to determine their effects; (2) one 
should distinguish between their therapeutic and toxic 
properties, which (3) are not always clearly distinguish-
able, except by dose; and (4) the effects of chemicals have 
a degree of specificity. In the standard toxicology science 
textbook referenced above, a poison is introduced as:
[A]ny agent capable of producing a deleterious 
response in a biological system, seriously injuring 
function or producing death. This is not, however, 
a useful working definition for the very simple 
reason that virtually every known chemical has the 
potential to produce injury or death if it is present 
in a sufficient amount. (Klaassen 2013: 17)
This points to the most fundamental concept in modern 
toxicology, the dose-response relationship, although the 
characteristics of exposure are known to further depend 
on the route, site, duration, and frequency of expo-
sure. From the toxicological perspective, all substances 
are potentially poisons, including food and medicine. 
Interestingly, the concept of ‘hormesis’ suggests that 
“some nonnutritional toxic substances may also impart 
beneficial or stimulatory effects at low doses but that, 
at higher doses, they produce adverse effects” (ibid: 25; 
see Calabrese and Blain 2005). This results in a U-shaped 
dose-response curve. In this sense, there is no clear-cut 
poison/medicine dichotomy, but rather a spectrum of 
biological effects (legislative, regulatory and medical 
frameworks notwithstanding). 
As a starting point for my critique on the applicability of 
Paracelsian toxicology6 to Tibetan medical formulas, it is 
important to note the ambivalence inherent in the scien-
tific definition of poisons quoted above, as well as in the 
complex nature of dose-response effects. Recent historical 
investigations of the European medicine cabinet also 
reveal “the multidimensional and dynamic role of drugs as 
poison and vice versa” (Pieters 2018: 10), questioning dose 
as the single determinant of their therapeutic/poisonous 
effects. Indeed, it appears that “[T]he double-edged sword 
of benefits and harms” (ibid: 12) has only been sharpened 
by the maturation of the fields of toxicology, pharma-
cology and the burgeoning pharmaceutical industry, as 
the quest for ‘pure ingredients,’ ‘precise dosages,’ and 
narrowly defined effects has “actually opened new avenues 
for mass poisoning in hospitals, nightlife, industry and the 
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battlefield.” These new chemical medications are founded 
on a legacy of eighteenth- and nineteenth-century ‘heroic 
medicine,’ with small doses that could be therapeuti-
cally effective but equally harmful. Pieters (2018) thus 
emphasizes that not just the dose but also the context of 
use defines what makes a poison, as he exemplifies in the 
case of injection of a highly toxic and expensive chemo-
therapeutic fluid against deadly cancer with more-or-less 
desperate patients and doctors in an increasingly commer-
cialized medical/pharmaceutical industry. 
The Gyüzhi (Rgyud bzhi, the Four Tantras)—Sowa Rigpa’s7 
canonical medical text, probably redacted in its current 
form in the fourteenth century (McGrath 2017)—however, 
states that all substances on earth are potentially medi-
cines: sa steng sman min ci yang yod ma yin (Men-Tsee-Khang 
2011a: 185). It does not explicitly say that all substances 
could be poisonous, yet it implicitly recognizes the bene-
ficial potential of ostensibly toxic things. In the Gyüzhi, 
medicine (sman) and poison (dug) are formally distin-
guished and separately discussed, for instance in the three 
chapters of the Oral Instruction Tantra which detail the 
classification of poisons and their cures. Anything benefi-
cial can be referred to as men (sman) in Tibetan language, 
while anything harmful is duk (dug). Yet, in Tibetan 
medical theory and the subfield of medicine making (sman 
sbyor) in particular, both terms acquire multiple and more 
precise meanings (Sonam Dolma 2013). A comprehensive 
account of the textual and theoretical bases underlying 
men and duk is beyond the scope of this article. Instead, I 
illustrate ethnographically how aspects of amchi discourse, 
medicine-making and prescription problematize a rigid 
poison/medicine dichotomy in practice, focusing on 
issues of dosage and ‘side effects.’ The selected obser-
vations of reformulation, detoxification, compounding, 
and clinical consultations that follow reveal the fluid, 
contextual nature of potent substances. Dosage plays a 
vital role, but it is not the central paradigm. Instead, these 
practices locally shape the poison-medicine spectrum in 
concert with multiple environmental and clinical factors. 
Moreover, when amchi consider the dose of substances, 
the focus is manifestly not on the ‘single chemical entities’ 
which are ‘active principles’ in modern toxicology and 
biomedical pharmaceuticals (see Butler 2019; Tidwell and 
Nettles 2019). 
Leaving aside heavy metal contamination and poisoning— 
of which the detection and media coverage played a role in 
the politicization of Tibetan medicine in exile (Kloos 2008: 
35-36, 2017: 148-150)—bongnak black aconite may well be 
one of the potentially most toxic substances used in Sowa 
Rigpa (Ma et al. 2015). Aconite poisoning, mainly in the 
form of acute and possibly fatal cardio and neurotoxicity, 
is a rare but well-known phenomenon, especially in East 
Asian countries. It is often related to faulty identification 
and processing of Chinese medicines (Chan 2009, 2011; 
Nyirimigabo et al. 2015; Singhuber et al. 2009).8 These 
studies, however, presume that the toxicity (and efficacy) 
of aconite can be narrowed down to the binding to and 
stimulation/inhibition of molecular receptors by aconitine 
and related alkaloids. Yet none of the amchi I interviewed 
and worked with think in these terms, which should not 
come as a surprise. I argue that amchi attend to broader 
understandings of potency and efficacy, which allows for 
an attunement to ‘ecologies of potency’ in which phar-
macists and their techniques, clinicians, patient bodies, 
and local formulations of Garuda 5 and other substances 
are enmeshed. In line with Sienna Craig’s Efficacy and the 
Social Ecologies of Tibetan Medicine (2012), this perspective 
provides fertile ground for better understanding the 
effects of potent substances. Craig maps the multiple ways 
in which human-environment interdependencies shape 
the efficacy9 of Tibetan medicine in her multi-sited ethnog-
raphy in Nepal and Tibetan areas in China.  
She defines efficacy as: 
[…] produced at the intersections of ritual action 
and pharmacology, within distinct social ecologies. 
Efficacy is a measurement of micropolitical power, 
biopsychosocial effects, and cultural affect. It is 
an intersubjective phenomenon, by which I mean 
that one cannot really know whether a medicine or 
therapeutic approach is efficacious until a practi-
tioner makes and/or prescribes it, a patient uses it, 
and then reacts to its use. (Craig 2012: 7)
I subscribe to her nuanced definition, which recognizes the 
medico-ritual nexus and its social, sensorial, and material 
embodiment. However, my focus here excludes ritual 
contributions to efficacy (which in fact cannot be isolated 
as such, also in the case of Garuda 5).10 It also does not 
elaborate much on the complex of psychological, sociocul-
tural and political-economic layers that infuses medicines 
with power, which has constituted the main object of 
study within the social sciences (see Coderey 2019). 
Regrettably, “medical anthropology has seemed hitherto 
to lack in full engagement with phytomedical reality, 
and the acceptance that the health care practices of most 
people on this planet depend on plants and animals” (Ellen 
2006: 10), reflecting a problematic gap between medical 
anthropology and ethnobotany (Waldstein and Adams 
2006; Hsu 2010). Anthropologists of pharmaceuticals have 
equally ignored materiality and “have left the discussion 
of the drugs themselves and their physiological effects 
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to biomedicine, accounted for socio-cultural aspects, and 
thereby inadvertently reinforced the Cartesian dualism 
that has set the agenda for the medical anthropological 
project” (Hsu 2010: 23). I aim to bridge this problematic 
divide through a heightened anthropological sensitivity 
to plants and their properties, by highlighting some of the 
more material, technical, and bodily dimensions which 
determine the activity of the Garuda 5 formula.11 I also 
expand Craig’s approach by including the full spectrum 
of potency—the ‘good’ and the ‘bad,’ the ‘wanted’ and the 
‘unwanted’—without presuming the universal validity of 
biomedical notions of efficacy, toxicity, and side effects. In 
this move, I am inspired by Margaret Lock’s ‘local biolo-
gies’ (Lock 1993, 2001: 483-487). Moving beyond the narrow 
purview of ethnomedicine as well as meaning-centered 
analyses, Lock saw the need early on to transcend the 
nature/culture dichotomy and to question the epistemo-
logically untouchable position of both the human body and 
the medical sciences as ‘natural’ categories. Conceiving 
the body ecologically as a dynamic microcosm based on 
and overflowing in the local environmental macrocosm, I 
argue that the Gyüzhi’s poison/medicine dichotomy is, in 
effect, a spectrum of potent possibilities shaped by local 
interactions and bodily configurations.
Academic coverage of what scholars have termed ‘Tibetan 
pharmacology’—including its principles (Cardi 2005-2006, 
Hofer 2014), its interrelationships with Buddhist ritual 
(e.g., Gerke 2017), medical formularies and knowledge 
transmission (Gerke 2018), and textual-historical analysis 
of key concepts such as potency (nus pa) and substitution 
(tshab) (Czaja 2015; 2017)—is significant and growing. 
However, there is still a lack of close ethnographic atten-
tion to the material flows and frictions that make up the 
potency of Tibetan medical substances (but see Blaikie 
2014: 260-317, 2015; Blaikie et al. 2015; Chudakova 2015, 
2017; Gerke 2013a). Building on Barbara Gerke’s long-
term anthropological research on toxicity in Sowa Rigpa, 
I recognize the crucial yet controversial entanglements 
between the healing and harming potentials of substances. 
A three-year project on pharmacological detoxification 
methods with practitioners in India and Nepal led her to 
investigate tsotel (btso thal), a highly processed and expen-
sive organometallic complexed mercury sulfide compound 
considered to be “the pinnacle of Tibetan pharmacology” 
(Gerke 2013a: 123) and an essential ingredient for several 
of the most complex, potent, and popular Tibetan medi-
cines named ‘precious pills’ or ‘jewel pills’ (rin chen ril bu). 
Gerke describes a dilemma faced by the Tibetan medical 
community: tsotel (if processed correctly) is perceived 
by them as the supreme medicinal substance, whereas 
the mercury it contains is seen as the most dangerous 
neurotoxin in bioscientific circles and is implicated in 
poisoning scandals. While Tibetans do not doubt its 
benefits and are keenly aware of mercury’s toxicity in 
unprocessed form, practitioners and institutions are chal-
lenged to prove its safety. This focal shift from efficacy to 
safety was noticed by Gerke (2015) as a more general trend 
in the biomedical and regulatory literatures on Asian  
medicines (cf. Schrempf and Springer 2015, and  
especially Kadetz 2015a, b).
Within medical anthropology, discourses of harm reduc-
tion, prevention, and risk have been found to reinforce 
prejudice towards marginalized groups under the guise of 
scientific objectivity, engendering complex dynamics and 
politics of responsibility (Lock and Nichter 2002: 11-14). 
In this article, I am sensitive to how modern biomedical 
notions of risk can be mobilized to condemn ‘traditional 
medicines’ through their conception as hazardous entities. 
These sensitivities notwithstanding, biomedical notions of 
‘risk’ and ‘side effect’ continue to play an insidious role in 
what follows.
Ethnopharmacologist Nina Etkin (1992) critically analyzed 
the reductionist biomedical definition of ‘side effects’ and 
how these effects are interpreted and employed in unex-
pected ways in various sociocultural realities, as, in Etkin’s 
seminal study on the indigenization of pharmaceuticals 
by the Hausa of rural northern Nigeria. She argues that 
“the primacy or subordination of effects depends on why 
a medicine is administered, the intentions of the user 
and prescriber, and the anticipated outcome—in short, 
its cultural context” (Etkin 1992: 102). Contrary to the 
general opinion, she finds, traditional medical systems 
relying mainly on a pharmacopoeia of plants are markedly 
sensitive to a multiplicity of effects. Indeed, as plant-
based medicines are complex mixtures to which multiple 
benefits are often ascribed, one would logically expect 
there to be more ‘secondary’ effects as well. Herbalists 
thrive on their awareness of this complex chemical 
ecology (Johns 1996) far removed from the unrealistic 
one-dimensional efficacy/toxicity or main/side effect of 
highly concentrated pharmaceutical molecules. The myth 
that pharmaceuticals have both stronger efficacy as well 
as less side effects belies their sociocultural and biological 
complexity. Secondary effects are relegated to a post-mar-
keting rhetoric of ‘noncompliance’ and ‘misuse,’ masking 
what are often purposeful appropriations by its users. 
The following three sections are mainly based on my 
doctoral fieldwork at the Men-Tsee-Khang, carried out 
during several extended stays between 2013 and 2015 
over a duration of roughly six months. My work there 
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was part of an officially sanctioned, mutually beneficial 
collaboration. I taught Tibetan medical students botany 
and staff English on a weekly basis for several months 
and copy-edited a book on Tibetan medicinal plants (now 
published: Tsultrim Kalsang 2016). In return, I was able to 
access amchi working in the Materia Medica Department, 
the Pharmaceutical Department (‘the pharmacy’), the 
quality control lab, and the branch clinic of Gangchen 
Kyishong (‘Gangkyi’). In the next heading, I first intro-
duce how Men-Tsee-Khang amchi talk (or do not) about 
scientifically defined risk and safety issues, relying on 
textual ideals. I then move into the pharmacy, where it 
turns out the potency of Garuda 5 in particular has to be 
carefully adapted and crafted to local bodies and ecologies. 
In the clinic, this medicine occupies an essential niche in 
multi-compound prescriptions, which adds to the (social-)
ecological interactions that make its potency on a  
different scale.
Textual Ideals and General Amchi Discourse on Safety 
and Side Effects
On the third day of the Eighth ICTAM12 conference in 
South Korea (September 9-13, 2013), Men-Tsee-Khang 
Dr.13 Jamyang Dolma presented on ‘The Effectiveness and 
Safety of Traditional Tibetan Medicine in the Treatment 
of Challenging Diseases.’ Jamyang Dolma first emphasized 
that Sowa Rigpa has a long history of empirical observa-
tion and research, which ensures its safety and efficacy, 
and that practitioners do not question the reliability of the 
classical texts nor the efficacy of their system. However, 
globalization has brought the need for ‘evidence’ and 
modern scientific studies even if these do not fit well with 
traditional concepts. She then summarized the results of 
clinical research undertaken by the Men-Tsee-Khang on 
diabetes, hepatitis B and hypertension, and on processed 
mercury. Her conclusion was that Tibetan medicine has 
been proven to be very beneficial, that “it is totally safe,” 
and that ‘authenticity’ is the key to its safety and efficacy. 
About a week later, during a five-day introductory course 
at Men-Tsee-Khang college (September 16-21, 2013), Dr. 
Nyima Gyaltsen gave a lecture on the ‘Seven Limbs’ (yan 
lag bdun), which detail the proper processing of herbs 
into medicine according to the Four Tantras, and came 
to a similar conclusion: “This [adhering to these textual 
standards] is why everyone knows that Tibetan medicines 
have no side effects.” These bold statements do not imply, 
however, that amchi mindlessly accept that all their medi-
cines are equally beneficial and by extension ‘safe’ in all 
circumstances. Their aim here was to validate the efficacy 
of properly produced Sowa Rigpa formulas vis-à-vis a 
professional and student audience. In their statements, 
Tibetan doctors assume that the practitioner-patient 
interaction modulates prescription and usage. Dr. Rigzin 
Sangmo from the Research & Development Department 
exemplified this issue in her coming to terms with my 
questions on the existence of side effects (interview, May 
1, 2014): “for example, if you take cold [potency] medicines 
for a very long time this might negatively affect your 
digestion, but the practitioner can foresee this and adapt 
the medicines accordingly.” The practitioner attunes  
the qualities of the medicine to the constitution and 
current situation of the patient, which I highlight further 
as one of several opportunities to attune to the local ecol-
ogies of potency in the section on prescription practices 
below. She disliked attributing side effects to Tibetan 
medicines—one of the negative hallmarks of biomedical 
drugs for which Sowa Rigpa is globally represented as a 
natural, harmless complement or alternative—but did not 
deny the possibility of ‘adverse reactions’ such as constitu-
tional incompatibility or allergies.
Saying that Tibetan medicines have side effects is often 
taken as a smear on the whole system, a lack of trust in the 
practitioner’s traditional expertise, the classical texts or 
even the Medicine Buddha in extremis. These statements 
are part of a larger discursive trope expressed by both 
practitioners and patients that influences healthcare 
perceptions and decisions in the ubiquitous scenario 
of medical pluralism in Dharamsala (Prost 2008: 36-41, 
58-60). It also feeds into its globalization and spread into 
alternative medicine and wellness markets (Janes 2002). 
Stereotypically, biomedical pharmaceuticals are strong, 
have rapid effects but might bring about adverse reactions 
whereas Tibetan medicines are soft, slow-acting, natural, 
and eradicate the root-cause of the disease (see Besch 2006: 
191-194 for the same trope in Spiti).14 On top of that, what 
a Tibetan in Dharamsala might consider a minor nuisance 
as part of the healing process, European patients may 
consider a problematic side effect. Engaging with Indian 
road traffic made abundantly clear to me the very different 
perceptions of risk and danger involved. As Dr. Tsultrim 
Kalsang explained to me, taking medicines can have 
unpleasant but necessary effects:
Sometimes people taking khyung lnga or other 
strong medicine feel uncomfortable. It is not going 
to worsen, sometimes it gives more [healing] effect 
[in the end]. It takes time. If it continues like this, 
then you have to stop [taking the medicine]. Two 
or three days is ok. You need some movement, 
without movement there is no effect. A little bit 
worse, going down [purgation] or up [emesis]. If 
I have a medicine for constipation and get loose 
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motion, then the medicine gives effect. It doesn’t 
mean there is another disease. It is the effect. If I 
take medicine for constipation with no effect: no 
movement, still the same as before, [then] what is 
the use of medicine? (Interview, July 17, 2015)
During my fieldwork and in conversations with practi-
tioners and patients, I came across only very few instances 
where Tibetan medicines were deemed to have had a 
negative influence on people’s health. However, some 
reported unintended consequences of taking Garuda 5 are 
relatively severe: burning and numbing sensations of lips 
and tongue, itchy throat, dizziness, fainting, and weak-
ened heart rhythm. Yet these effects have equally led to 
adaptations in Garuda 5’s formulation, compounding and 
prescription, as is detailed in the following two sections.
Reformulating, Detoxifying and Compounding Garuda 5 
in the Pharmacy
When I asked Dr. Tsultrim Kalsang about the potential 
dangers of taking Garuda 5 (interview, April 19, 2014), he 
explained to me that the amount of Garuda 5 that will 
be prescribed first of all depends on the condition of the 
patient (being careful with children and the elderly) and 
the nature and severity of the disease (a stronger disease 
may need a higher dose). Depending on which subtype of 
bongnak and its strength (as judged by root color, appear-
ance, and sensation on the tongue), however, the method 
for detoxification may vary. The quality and availability 
of natural resources, itself determined by their habitat 
and harvesting patterns, impacts pharmaceutical practice. 
Practitioners need to be sensitive to this local ecology. 
Tsultrim Kalsang, a Tibetan medicinal plant expert 
stationed at the Materia Medica Department, has repeat-
edly been consulted by the pharmacy to confirm that the 
roots are of the right kind. He informed me that prolonged 
boiling of the roots in water, or treatment with cow milk 
or urine can be undertaken, if necessary, to transform 
poison into medicine.15
Dr. Penpa, who oversees the day-to-day production 
of medicines at Men-Tsee-Khang’s Pharmaceutical 
Department, added that effectively the quantity of  
aconite is usually reduced to levels below what is  
indicated in formularies:
It is the case. Because in earlier times people were 
stronger, not because of [the presence of] this 
poison. They could take this amount of tsenduk. 
These days people more easily get the effect. So, 
we have to reduce it. […] Not only for this tsenduk, 
also for these burning cones: moxa. Before we used 
big cones. Now we cannot use the bigger sizes, we 
use very small ones. Earlier, people were used to 
hard work. They had good energy in their body, 
they could take all this. These days people are more 
relaxed. […] Usually tsenduk is not in huge quantity 
in the medicine, but we had to reduce this [further] 
slightly. (Interview, April 21, 2014)
“The bodies of people nowadays have become frail due 
to a lack of manual labor,” was an observation echoed by 
several Tibetan doctors I met. Undoubtedly taking the 
harsh lifestyle of nomads and farmers on the high Tibetan 
plateau as a reference for optimal health, medicines must 
now be adapted to the ‘docile bodies’ (Langford 2007) of 
Tibetan exile, Indian, and ‘Western’ patients. Following 
Blaikie’s (2015) argument on the multiplicity and contin-
gency of ‘classical formulas’ in real-world pharmacy 
practice and the spate of research on industrial reformu-
lation (Pordié and Gaudillière 2014; Pordié and Hardon 
2015; Schrempf 2015), variations in the composition of 
Garuda 5 should not come as a surprise. However, in 
comparing the small number of English-language publi-
cations detailing Tibetan formulations, it seems that the 
variation is relatively minor. Bhagwan Dash (1994), an 
Ayurvedic scholar-physician, Smanla Phuntsog (2006), a 
lineage-based Ladakhi amchi, and Jigme Tsarong (1986), 
Tibetan exile and former Men-Tsee-Khang director, 
basically agree on the formula. This may be due to the 
standardizing effect of the Four Tantras,16 as well as wide-
spread reliance on the Excellent Vase of Elixirs (Bdud rtsi’i 
bum bzang) by Lhasa Mentsikhang’s founding director 
Khyenrap Norbu (Mkhyen rab nor bu, 1883-1962). The 
latter is a foremost reference for pharmacists operating in 
Tibet, India, and beyond, especially on ingredient quanti-
ties which are seldom published (Khyenrap Norbu 2007: 
150-151). Yet, when one compares these textual formulas 
with an actualized composition of Garuda 5, a different 
story emerges (Table 1). Nowadays at Men-Tsee-Khang’s 
pharmacy, the amount of aconite is generally much lower 
(from 25% to less than 10% of the total weight in this case), 
and musk (gla rtsi) is substituted by the resin of gul nag 
(the black type of gu gul, a primary component of Indian 
dhoop incense).17 The aconite/myrobalan weight ratio is 
1/5 instead of 1/2 in Khyenrap Norbu’s formulary, which 
likely further decreases aconite’s toxicity (and potency) in 
addition to the difference in amount in itself.18
On February 27, 2014, 634 kilograms of Garuda 5 was 
compounded under Dr. Penpa’s supervision, following the 
recipe outlined in Table 1. Arriving at the third ingredient, 
menchen, he noted that: “This time we put not so much, 
because it is very strong energy. […] These days first we 
have to clean it, then we have to boil it for a little bit to 
reduce this…how to say…potency, yes maybe duk.” This 
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quote directly points to the potentially close relation-
ship between potency (nus pa) and toxicity (duk), while 
highlighting the need for manipulation of pharmacological 
activity. Senior pharmacy doctors advise on how long the 
roots should be boiled, depending on the nature of each 
batch and their experience.20 Pharmacists must recognize 
the impact of local ecologies (e.g., different subtypes and 
potencies of Aconitum), but also pay attention to how these 
interact with and shape lived bodies. Focusing on the use 
of aconite in Garuda 5, we can therefore speak of local 
ecologies of potency. Figure 1 offers a general overview of 
the pill-making process at Men-Tsee-Khang’s pharmacy, 
which I interpret as a step-wise modulation and optimiza-
tion of potency (see van der Valk 2017: 236-238 for a more 
detailed description). 
As Dr. Nyima Gyaltsen indicated in an earlier quote, the 
“seven essential limbs of standardization” (translation of 
yan lag bdun in Men-Tsee-Khang 2011b: 135) play a central 
role in the putative absence of ‘side effects’ in Sowa Rigpa 
in general. The seven limbs are listed in the last of the Four 
Tantras, in chapter 12 on herbal compounds, and include 
dukdön (dug ’don), the ‘removal of toxic substances’ (ibid: 
135). These unwanted portions of medicinal ingredients 
(e.g., leaf petioles, flower sepals, fruit stones) are not 
considered to be acutely poisonous in the pathological 
sense, but their coarseness hampers the digestive fire (me 
drod) and harms the body constituents (lus zungs bdun). 
However, this relatively ‘simple pre-processing’ (following 
Saxer 2013: 68) does not seem sufficient for tsenduk, 
which requires careful, extra attention. Although still 
far removed from the complexity, duration, and cost of 
processing or ‘taming’ (’dul ba) mercury (cf. Sonam Dolma 
2013: 114-116; Gerke 2013a),21 Dr. Penpa stated that tsenduk 
needs ‘real’ detoxification. As was confirmed by Dr. Tsering 
Norbu, who worked in the pharmaceutical department for 
several years in the early nineties, menchen roots are boiled 
in distilled water at Men-Tsee-Khang but are sometimes 
also used directly. He is the author of a large book of more 
than six hundred pages in Tibetan that compiles materia 
medica and the formulas in which they are represented 
from classical Sowa Rigpa texts (Tsering Norbu 2005). He 
found that boiling in water was not described as a detoxifi-
cation method for menchen.22
Maybe some experienced doctors [in the past] did 
it like that. But [another form of] detoxification is 
mentioned. First you have to make ash, [still hot 
with] fire in the wood. A little bit of fire. After all 
the wood is burned, [take] a little bit of warm ash. 
Put powder of Aconitum in a pan, then put it in the 
ash, and cover [the pan] with paper. After a few 
minutes, the paper becomes wet. The powder color 
becomes a little yellow, then ... Not detoxified, not 
like mercury. Mercury has many processes. [But its] 
energy has become less, that is the idea.  
(Interview, July 21, 2015)
Interestingly, Dr. Tsering Norbu specifies that, in the case 
of aconite, the aim is to decrease its ‘energy’ (nus pa). The
 
Khyenrap Norbu’s ‘authentic Garuda 5’ 
(khyung lnga tshad ldan) textual formula
 
Men-Tsee-Khang’s actualized formula (batch compounded 
on February 27, 2014, under supervision of Dr. Penpa)
a ru (Garuda’s flesh) 40 srang (50%) a ru (Terminalia chebula Retz.), pitted fruit 250 kg (39%)
ru rta (bones) 10 srang (13%) ru rta (Saussurea costus (Falc.) Lipsch.), root unspecified
shu dag (tendons, rgyus pa) 6 srang (8%) shu dag (Acorus calamus L.), root unspecified
btsan dug (heart) 20 srang (25%) sman chen (Aconitum sp.), tuberous root 55 kg (9%)
gla rtsi (blood) 3 srang (4%) gul nag (Commiphora mukul (Hook. ex Stocks) Engl.), resin unspecified
79 srang (100%)  634 kg (100%)
Table 1. Comparison of an authoritative textual formula of Garuda 5 with an actualized composition at the Men-Tsee-Khang.19
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Figure 1. The main steps of rilbu (ril bu, rolled pill) production at Men-Tsee-Khang’s pharmacy, left to right and top to bottom. Pre-processing (in this 
case, manual sorting of spang spos), weighing and dosing of raw materials (here of Tikta 8), grinding, mixing, pill rolling, size checking, drying (of Agar 
35), and counting, labeling and packaging (Garuda 5). 
(van der Valk, 2014)
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heat-based potency-modulating method he describes is 
laid out in the text Lag len gces bsdus by Deumar Tendzin 
Püntsok (De’u dmar Bstan ’dzin phun tshogs, born 1672, 
Deumar Tendzin Püntsok 1970: 532-549). Tsering Norbu 
said he has seen this being done at Lhasa Mentsikhang 
when he was there in the eighties. Different processing 
methods are currently used in different contexts, but 
Tibetan doctors in Dharamsala are confident that there, 
too, the potency of bongnak has been attenuated.23 
Pre-processing, detoxification and compounding tech-
niques are either described superficially or not at all, 
even in major pharmacy or menjor (sman sbyor) textbooks 
(Blaikie 2014: 267-270; Cardi 2005-2006: 99, 105). These 
experientially-based ‘pith instructions’ (man ngag) are 
orally transmitted and often considered secret, thus 
inviting high diversity in practice.
Eventually, I discussed the issue with Dr. Penpa Tsering 
(Interview, July 18, 2015). He is a very experienced and 
well-known menjor expert who resigned from Men-Tsee-
Khang to lead his own production named Kundey Khangsar 
Tibetan Herbal Products, not far from Dharamsala. 
Although he agrees with the other, more junior Dr. Penpa 
currently working in the pharmacy that people were 
stronger in ancient times, he claims it is not possible to 
identify the variety of different bongnak subtypes on the 
market reliably as Tsultrim Kalsang does. In line with 
Tsering Norbu, Penpa Tsering maintains that menchen does 
not need to be detoxified as is done in Ayurveda: arura, 
Garuda 5’s principal ingredient, controls its toxicity. There 
is considerable variation in potency due to harvesting 
time and location, amongst other factors, and this should 
be assessed by tasting and testing the effect of the Garuda 
formula after compounding. 
VDV: You say you have to know how toxic menchen 
is to know the dose. How do you know how toxic it 
is? Can you taste it or see it?
PT: No, no. [Only] after making the pills. We have to 
see by experience how much we have to put. After 
making the pills, we are trying them. If it is okay 
[then we can use them], if the toxicity is high then 
we don’t have to use that one. We can do like this 
also: we mix [the pills] again, compounding, putting 
less or not putting [extra] menchen. Putting other 
things will lessen the toxicity.
Making and taking Garuda 5 is clearly not without danger 
to pharmacists and patients. If adverse effects occur and 
are reported, one is advised to have some Tibetan noodle 
soup (thug pa) or yoghurt, and to rest. The dosage may also 
be reduced, for instance from three or four to only one or 
two small black pills. In the practical setting of menjor, safe 
and potent medicines are not a given, but are the contin-
gent result of a series of carefully executed procedures. 
Experience, skill, and sensory perception are sine qua non 
for the modulation of the poison-medicine spectrum. As 
ethnopharmacological studies have shown, organoleptic 
assessment is a key criterion for the classification, selec-
tion and medicinal use of plants that is both individually 
and culturally specific, reflecting differing notions of 
illness and efficacy (Pieroni and Torry 2007; Shepard 2004). 
Nonetheless, as put forward by Etkin (1992: 103), indige-
nous healers in many places—and biomedical physicians to 
some extent—are known to apply ‘side effects’ as  
dosage markers, which is also the case for Garuda 5.25  
As Cardi (2005-2006) details, Tibetan practitioners regard 
single-ingredient herbal medicines as inferior in efficacy 
and potentially more harmful compared to multi-com-
pound formulas where the therapeutic actions of the 
ingredients are coordinated, negative effects balanced out, 
and where the composition may be adjusted to individual 
patients. Throughout, the aim is to obtain a potent  
medicine that is also ‘smooth’ (’jam). From a Tibetan 
medical viewpoint, then, unwanted effects are likely to 
arise if the medicines have been poorly manufactured  
and/or unsuitably prescribed. 
Prescribing Garuda 5 in the Clinic
An energetic seventy-year-old Indian woman from the 
nearby village of Sidhbari entered the consultation room 
while her husband waited outside. Dressed youthfully and 
wearing strong perfume, she sat down and put her iPhone 
on the office table. She immediately started summing up 
her ailments in English interspersed with Hindi, describing 
her serious skin disorder that had spread over her arms 
and legs at the top of the list:
It is not psoriasis or scabies. An allopathic doctor 
said it was allergic eczema, but I didn’t want the 
cortisone. The skin peels off, but it keeps coming 
back. I take thyroxin every day. I took Tibetan med-
icine for years for bronchial asthma, it got better 
but was not completely cured.  
(Observed consultation, May 6, 2014)
While taking the pulse, Dr. Sonam Wangmo noted that 
internal fever was present; it was a very hot pulse. The 
lady also had a mkhris pa (‘bile’) constitution. Sonam 
Wangmo advised to avoid lemon and sour yoghurt. The 
patient replied she was a strict lacto-vegetarian. Her 
sleep was bad, and she wakes up every half hour. The 
amchi summoned another senior female practitioner 
from the adjacent room to discuss the case. Together they 
concluded that there was indeed a chronic ‘hidden fever’ 
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(gab tshad) and that chuser (‘yellow fluid’) was disturbed. 
The doctor explained to the patient that because of her 
age, less strong medicines were advisable. The medicines 
should be taken with hot water rather soon after eating. 
After the patient had left, Dr. Wangmo explained to me 
that taking high doses of strong medicine could result 
in low blood pressure, which may lead to fainting. These 
reactions are not considered side effects, but are instead 
interpreted as a consequence of prescribing medicines 
inappropriate for the patient’s current state. Thangchen 25 
was prescribed in the morning time to purify the blood and 
separate the hidden fever from it. After lunch, Ngülchu 18 
was prescribed to reduce chuser and to ward off afflictions 
by nāga (klu). Skin problems are commonly related to these 
nāga serpent spirits (although this was not mentioned 
to the patient), and here the processed mercury sulfide 
complex is particularly effective. Two combinations to be 
taken on alternate days were prescribed for the evening: 
Gurgum 13 plus Khyung Nga Nila26 (for the liver and 
impure blood and to fight lymph-related infection, respec-
tively) and Pökar 10 (against itching skin) plus Khyung Nga 
Nila. To smoothen the skin, Tripa lotion was prescribed.
I asked a number of amchi what Garuda 5 is commonly used 
for, and the keywords I got back were ‘infection,’ ‘inflam-
mation,’ and ‘pain’.27 Typical examples I was given were to 
keep one pill in your mouth in case of painful toothache, or 
to take a few against knee pain or acute headache caused 
by srin (a technical term frequently applied to parasites 
and pathogenic micro-organisms). Several amchi, as well 
as patients, referred to Garuda 5 as “a sort of antibiotic” 
with the formula’s fast-acting antibacterial effects in mind. 
During my time observing consultations with Dr. Sonam 
Wangmo at Gangkyi clinic (April-May 2014), I witnessed 
more than a dozen cases where Garuda 5 was prescribed. 
Amchi-la confirmed that Tibetan patients will specifically 
ask for it when needed. Tibetan medicines, however, are 
not usually prescribed as a single formula—already a 
complex compound of processed natural ingredients—but 
as a combination of formulas to be taken before breakfast, 
after lunch and after dinner. On top of that, Garuda 5 is 
one of few formulas that is compounded and prescribed 
together with others, to be taken at the same time of day 
(as in the consultation summarized above): a third-order 
combination or compounding of compounds. Other exam-
ples of these ‘supercompounds’ include Pökhyung (Pökar 
10 + Garuda 5), Pangkhyung (Pangyen 15 + Garuda 5), 
Samkhyung (Samnor + Garuda 5), and Nyikhyung (Sendru 
Nyikyil + Garuda 5), all of which are widely known and 
used (cf. Penpa Tsering and Choelothar 2013). According 
to Sonam Wangmo, who has more than fifteen years of 
clinical experience, this complex ecology of substances 
is required to treat contemporary problems and diseases 
that have become more complicated.28 In contrast to 
nowadays, Dr. Wangmo added, senior doctors in ancient 
times were very sure about their diagnosis and preferred 
to wait and see the effect of single formulas, which they 
may have prescribed three times a day for seven days. 
Once again, the frailty of human bodies (and knowledge) 
is mobilized to explain for changes in Tibetan medical 
practice that seem to deviate from the classical ‘golden 
age’ of the past. Such statements are influenced by a larger 
Tibetan Buddhist and Hindu trope of degenerative times 
(Skt. kaliyuga), which has shaped Sowa Rigpa’s entangled 
intellectual history and innovation for centuries (Gyatso 
2015: 7-8, 137-138). In line with Gyatso, prescribing Garuda 
5 necessitates an empirical, medical mentality that gives 
ample attention to “the local specificities of the natural 
world” (ibid: 8); that is, to its local ecology of potency. 
Conclusion
On camphor we have a very impressive saying in 
Tibet: it is the king of the medicine, especially [due 
to its] very cold and rough nature. But if you don’t 
prepare it or compound it in a good way, it is very, 
very harmful. It should not be like poison, but very 
harmful. Because its rough nature increases rlung 
(wind). Now, at present in Tibet, we really don’t 
use that much camphor.29 […] The saying goes that 
this king [of medicine] will be harmful more than 
healing, kill more people than help people. […] 
Tsenduk, [black] aconite, is the king of poison. This 
will be helpful more than harmful. These two are 
compared. (Dr. Tenzin Thaye, Deputy Head of Men-
Tsee-Khang’s Pharmaceutical Department, Inter-
view, April 30, 2014)
The above quote, related to me by Dr. Tenzin Thaye, 
compares the effects of camphor and aconite—the respec-
tive kings of medicine and poison.30 It warns us that what 
is beneficial and what is harmful is not straightforward 
in Sowa Rigpa, and may even turn out to be opposite to 
our expectations. So, was Paracelsus wrong? In the case of 
Tibetan medical compounding and prescription practices, 
what counts is the potency of mixtures and not the effect 
of a single entity (see Schwabl and van der Valk 2019). It 
is the processing of and interactions between ingredients, 
and attunement to lived patient bodies, which ensures a 
‘smooth’ medicine. A priori distinctions between thera-
peutic and toxic effects are mere conjecture. In  
this dynamic ecology of potency, the dose remains 
important but is not the ultimate criterion. These inter-
woven biological and cultural dimensions of efficacy and 
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toxicity have long been recognized and encapsulated in 
non-dichotomous, ambiguous potency concepts such as 
the Greek pharmakon (Rinella 2010), the Amazonian rao 
(Shepard 2004) and the Zulu term muthi (Ashforth 2005). 
Although Ayurveda and Chinese medicine have separate 
words for ‘medicine’ and ‘poison’ like Sowa Rigpa, it is 
now clear that this need not imply that their intentions 
and outcomes can and should be easily distinguishable.31 
To come to this conclusion, I built on Craig’s (2012) Social 
Ecologies to unpack medicine/poison and ‘main’/’side’ 
effects as the contingent result of dynamic plant-practi-
tioner-patient body interactions and practical modulations 
of potency in the pharmacy and the clinic. These local 
ecologies of potency are sensorial, at once social and 
chemical, and involve multiple human and nonhuman 
actors and labor. 
Although biomedical definitions are spreading and hybrid-
izing with Asian medicines, safety, efficacy and toxicity 
remain situational, multi-dimensional concepts. The more 
pressing question then becomes how negative effects 
might be documented and averted by menjor experts and 
in the clinic, where proper diagnosis of the patient plays a 
central role in determining which medicines have suitable 
activity profiles. The formulation of rilbu is a step-wise 
potency modulation process that removes, transforms 
and balances out or ‘smoothes’ the useless, coarse and 
poisonous elements of materia medica. In the daily workings 
of the pharmacy, however, practical and experience-based 
decisions have to be taken on the exact details of this 
process. Which types of aconite can be used as ‘the great 
medicine’ (menchen), what amount, and should the roots 
be pre-boiled or not? Different opinions and methods 
abound, but all amchi agree that extreme caution should be 
exercised. The menjor experts I interviewed further agreed 
that the actual amount of aconite to be added depends on 
the strength of the raw material and on the strength of 
patient bodies nowadays, resulting in a considerably lower 
dose than what is recorded in historical and contemporary 
references. The real risk then lies in the uncritical adop-
tion of textual formulas by inexperienced producers, or 
not attending to the local ecologies of potency manifested 
in the interaction between Tibetan medicinal plants, 
skilled producers-with-machines, and the local biologies 
of patient bodies. In the clinic, practitioners diagnose the 
patient’s constitution and imbalances of the elements and 
prescribe medicines as part of a larger treatment regimen 
that further considers intricate relationships with food  
and environment. 
Garuda 5 fulfills its medicinal role within this clinical 
encounter as a compound among compounds, which 
I described as another level of the balancing act that 
maximizes its healing potential. If we approach the activity 
of potent substances as a multidimensional spectrum 
constituted by its contingent socio-material surroundings, 
there is no longer a need for simplistic dose dependencies 
or rigid poison/medicine oppositions. This is the case, at 
least, for the anthropologist struggling to overcome the 
hegemony of structuralist binary opposites. The aim here 
is not to falsify or eradicate the conceptual poison/medi-
cine divide, which continues to play a critical role in the 
minds of practitioners. I did not focus on how Sowa Rigpa 
texts theoretically cross the divide, but instead showed 
how this barrier is breached—not without risk—in prac-
tice. In this move, I am inspired by Janet Gyatso’s (2015) 
historical analysis of scholar-physicians such as Zurkharwa 
Lodrö Gyelpo (Zur mkhar ba blo gros rgyal po, 1509–1579), 
who forged a more pragmatic and empirical ‘medical 
mentality’ in productive tension with classical Buddhist 
scholasticism and soteriology.
Understanding categories to be but provision-
al heuristics that stand for a far more complex 
situation on the ground, medical thinkers came to 
recognize that opposing taxonomical pairs do not 
reference polar opposites in reality. Rather, they 
are better understood as markers along axes that 
can often be asymmetrical and that in any case 
admit a wide array of permutations.  
(Gyatso 2015: 400)
Do Tibetan medicines have side effects? From a biomedical 
perspective, they might. But this is not the point. Building 
on Etkin (1992), ‘side effects’ are an artifact of a reduc-
tionist gaze fixated on often only one ‘active substance’ 
as ‘magic bullet’ targeting a molecular receptor, and the 
concomitant assumption that this mechanism automat-
ically leads to a distinguishable ‘primary effect.’ This 
view is hardly applicable to Sowa Rigpa, with its flexibly 
interpreted multi-compound formulas based on complex 
and processed natural ingredients that are indicated for a 
spectrum of culturally mediated symptoms and disorders 
(see Schwabl and van der Valk 2019). In this sense and 
in this sense only, Tibetan medicines indeed do not have 
‘side effects.’ This also places general amchi discourse on 
drug safety in a different light. I maintain that the material 
potency of Tibetan medicines is more coherently explained 
by starting with observations of actualized local medical 
practice. Promising developments in systems biology 
approaches notwithstanding, it is furthermore vital that 
Sowa Rigpa’s nuanced conceptualizations of potency, 
toxicity, and compounding take center stage in this 
endeavor (see Tidwell and Nettles 2019). 
122 |  HIMALAYA Spring 2019
Many Tibetan doctors continue to claim that Sowa Rigpa 
formulas are side-effect free as long as they are manu-
factured authentically and prescribed correctly. Given 
the data I have collected, it is impossible to maintain 
that Tibetan pills do not have the potential to harm the 
patient. It could be argued that it is epistemologically 
unfitting to expect the Men-Tsee-Khang to start taking 
stock of ‘adverse reactions’ the way science-driven 
toxicologists would. This would imply that Sowa Rigpa 
needs to be ‘improved’ or ‘modernized’ to be safe, which 
simultaneously installs biomedically biased institutions 
as the ultimate arbiters of safety, quality, and efficacy. Or 
is this perhaps the advent of a uniquely Tibetan alter-
native modernity that redefinines both ‘tradition’ and 
‘modern science’ as mass-produced Tibetan medicines 
enter capitalist markets (Kloos 2015)? Such a trajectory 
has been followed for more than a decade in the case of 
Ayurvedic, Unani, and Siddha drugs. In 2008, a national 
pharmacovigilance system was launched under the aegis 
of the Department of AYUSH and evaluated in successive 
committee meetings, following World Health Organization 
guidelines (Chaudhary et al. 2010; Thatte and Bhalerao 
2008). The ‘open-minded scientists’ (Ganguly 2012) part of 
this program maintain that “[a]lthough a technical term 
equivalent to ‘pharmacovigilance’ does not feature in 
Ayurvedic texts, the spirit of pharmacovigilance is vibrant 
throughout Ayurveda’s classical literature” (Chaudhary et 
al. 2010: 252). Notwithstanding possible benefits of such an 
approach for practitioners and patients, I argue that the 
very opposition between risk and benefit—as found in the 
biomedical assessment of risk/benefit ratios of pharma-
ceuticals32—is misleading when considering the dynamics 
of and correlation between toxic and therapeutic effects 
in Sowa Rigpa practice. While amchi may think in terms 
of duk and men, they also closely attend to and modulate 
the local expression of the poison-medicine spectrum in 
the pharmacy as well as in the clinic, where they rely on 
individual constitutional assessment. Finally, we should take 
into account that the very definition of risk and choosing 
between risky options is a politically and economically 
infused, value-laden selection process that is contingent on 
subjective, individual comparisons with daily-life dangers. 
Perhaps the risk is higher in some cases, but most likely so 
is the benefit. Researchers should not presume the univer-
sality of biomedical safety and toxicity notions based on 
ethnocentric and paternalistic assumptions. In this light, 
the effects of the on-going regulation and standardization of 
Sowa Rigpa and other healing traditions on the potency of 




1. The Garuda (Tib. khyung) is a popular mythical creature 
in both Hindu and Buddhist traditions which later merged 
with the Bonpo ‘sky-soarer’ in Tibet. This king of birds 
has the torso of a man and holds a nāga (serpent spirit) 
king between his hands and sharp beak. In Tibetan 
iconography, the Garuda assumes multiple roles and forms 
(Beer 2003: 74-77; see also Karmay 1993). The Garuda 5 
origin myth introduced here is also rooted in references 
from the Gyüzhi.
2. It appears that Aconitum spp. equally play a role in 
the Indian mythical origins of poison. Three alternative 
accounts of its origin are depicted and summarized in 
Dési Sangyé Gyatso’s monumental seventeenth-century 
set of Tibetan medical paintings (see Parfionovitch, Dorje, 
and Meyer 1992: 117-118). In the most prominent account 
various types of aconite are said to be derived from the 
shattered body of Poison Incarnate (Hālahāla), who was 
vanquished by the Hindu gods in their quest for the nectar 
of immortality.
3. Tibetan medical texts distinguish up to four main color 
types of bong nga: white (dkar), red (dmar), yellow (ser), 
and black (nag). Only the black type (bong nag) is said to 
be “poison as well as medicine” (Dawa 1999: 50, quoting 
Rin chen ‘khrungs dpe), and it is subdivided further into 
different forms with varying potency (cf. Parfionovitch et 
al. 1992: 77, Plate 31). The remaining three types neutralize 
different poisons; bong dmar and bong ser in fact alleviate 
poisoning by bong nag (Men-Tsee-Khang 2011: 205).
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4. Refer to Kloos (2008, 2015, 2017) for the history and the 
tightly interlinked cultural aspirations and politics of the 
Men-Tsee-Khang in the context of preserving ‘Tibetan 
medicine in exile.’ Men-Tsee-Khang positions itself as a 
guardian of tradition and is considered by many to be the 
prime institution in exile involved in the education and 
production of Tibetan medicine. 
5. “Alle Dinge sind Gift und nichts ist ohne Gift, allein die 
Dosis macht es, dass ein Ding kein Gift ist” (Paracelsus (1538) 
1965-1968: 510). The universal validity of this tenet is 
also increasingly being challenged by toxicologists, 
particularly in light of the chronic toxicity of endocrine-
disrupting contaminants, which turns out to be difficult 
to predict based on dose-response curves (Myers et al. 
2009). More recent biomedical research points out that 
timing is equally a crucial factor in the metabolism and 
detoxification of drugs (Gachon and Firsov 2011).
6. Here, ‘Paracelsian toxicology’ refers to the modern 
strand of basic toxicological science built on dosage as the 
foundational paradigm. Paracelsus’ own theories of poison 
are more complex, varied and idiosyncratic (Hedesan 
2018). Grounded in Aristotelian and Christian hierarchical 
views of nature as well as Hermetic-alchemical cosmology, 
some of his ideas do resonate with Sowa Rigpa. Notable 
examples include the reliance on intricate alchemical 
procedures to transform poison into medicine, and a 
focus on the stomach (the ‘inner alchemist’) and proper 
digestion in the elimination of harmful food essences 
(conceived as a type of poison).
7. ‘Tibetan medicine’ and its cognates are by far the 
most prevalent glosses for Sowa Rigpa (gso ba rig pa, ‘the 
science/knowledge of healing’) outside its Himalayan 
homelands. I nonetheless prefer the latter, as it is less 
ethnocentric and nationalist, and points to the textually 
grounded yet heterogeneous nature of this medical 
tradition (Adams et al. 2011; Hsu 2013; Craig and Gerke 
2016). The spelling ‘Sowa Rigpa’ (not Sowa Rikpa) is 
maintained, reflecting common usage. 
8. Chan (2009) reports that the estimated lethal dose for 
humans is about one gram of fresh plant material or 5 ml 
of alcoholic tincture, corresponding to 2 mg of aconitine 
and considering that the alkaloid content of the different 
plant parts varies significantly (roots and tubers > flowers 
> leaves and stems). The most prevalent Chinese medicinal 
species are Aconitum carmichaelii Debeaux (fu zi 附子, 
lateral roots; chuan wu 川乌, root tuber) and A. kusnezoffii 
Rchb. (cao wu 草乌, root tuber).
9. As Craig (2012: 6) notes, the most common Tibetan 
translation for efficacy is phan nus. This is a contraction 
of the words for benefit (phan thog) and potency (nus pa), 
effectively coupling the useful with the powerful.
10. Dr. Tsultim Gyatso, a Men-Tsee-Khang trained monk-
physician based in Choglamsar (Ladakh), presented Garuda 
5 as an example of a compound exhibiting ‘the potency 
of aspirational prayers’ (smon lam gyi nus pa). He related 
this to the Garuda legend mentioned in the introduction 
(Interview, September 18, 2018). This is, however, just one 
small example of a vast and understudied subject.
11. See Pordié (2014, 2015) for parallel attempts from 
the perspective of industrially (re-)engineered Ayurvedic 
proprietary medicines.
12. ICTAM stands for International Conference of 
Traditional Asian Medicines. It is the main event organised 
by IASTAM, the International Association for the Study of 
Traditional Asian Medicine.
13. The Central Council for Indian Medicine has recently 
officially recognized the medical qualifications of Sowa 
Rigpa practitioners who graduated from Men-Tsee-Khang, 
as well as three other institutions in India (Indian Medicine 
Central Council Act 1970, amended on April 5, 2018). This 
implies that registered graduates can legally adopt the title 
of ‘Dr.,’ which is also preferred by Men-Tsee-Khang  
amchi themselves.
14. In the clinical interactions I observed between amchi 
and Tibetan patients at Men-Tsee-Khang’s Gangkyi clinic, 
Tibetan medicines were not rarely employed to abate  
the side effects perceived by patients undergoing 
strong and prolonged biomedical treatments (e.g., for 
tuberculosis, hepatitis, and HIV), to support and protect 
weakened organs. A similar usage of ma ni ril bu was noted 
by Kloos (2010: 114).
15. Several experimental chemical analyses have 
confirmed that these traditional processing methods—also 
applied in Chinese medicine and Ayurveda—are effective 
at the extraction of diester diterpene alkaloids and their 
conversion into less toxic monoesters (Jaiswal et al. 2013; 
Nyirimigabo et al. 2015; Singhuber et al. 2009).
16. The components (without amounts) and their 
correspondence with Garuda body parts, their curative 
properties and potential supplementary ingredients 
(kha tshar) of Garuda 5 are the first to be listed in the pill 
chapter of the Subsequent Tantra (cf. Men-Tsee-Khang 
2011b: 90-91). Here, bi kha nag po is the heart of the Garuda.
17. Substitutions across botanical kinds and kingdoms 
are not uncommon in Sowa Rigpa (Czaja 2017; Gerke 2016; 
Sabernig 2011), and are not easy to explain fully based on 
the pharmacological principles of taste and potency.
18. Besides the total percentage of aconite in each 
formula, I also calculated the ratio between the weights of 
aconite and myrobalan. This second means of comparison 
between formulas makes pharmacological sense. A ru ra is 
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used in Tibetan medicines as a balancing and detoxifying 
agent, it thus neutralises potentially negative effects of the 
other ingredients. Phytochemically, chebulic myrobalan 
(Terminalia chebula Retz.) is known for its high tannin 
content. Tannins bind and precipitate proteinaceous 
molecules including alkaloids, which are considered to be 
aconite’s major active compounds.
19. This does not reflect all necessary (pre-)processing 
and detoxification procedures, neither does it include the 
addition of a black ‘iron essence’ (lcags rtsi) pill coating, and 
ritually empowered substances. The amounts of several 
Men-Tsee-Khang ingredients were left unspecified to 
respect their intellectual property rights.
20. Men-Tsee-Khang’s physico-chemical and microbial 
quality assessment lab detects the presence/absence of 
alkaloids in each batch of raw materials and products 
as part of their routine checks, but no standardization 
of alkaloid content is carried out as this would require 
quantification (and more advanced analytical machinery).
21. ‘Detoxification’ (dug ’don) and ‘taming’ (’dul ba) are 
only two amongst several terms and translations used to 
denote the processing (Skt. śodhana) of metallic mercury. 
Alternatives are ‘cooking,’ ‘purifying,’ and ‘perfecting’  
(see Gerke 2013b: 5).
22. Dash (1994, 11-12) warns the reader that tsenduk 
(which he considers to be a type of the Ayurvedic 
vatsnābha) is exceedingly poisonous and that it should be 
detoxified before use, advising prolonged soaking in cow 
urine until the purified aconite does not produce tingling 
sensations or numbness on the tongue. Khyenrap Norbu 
(2007: 151) on the other hand mentions soaking it in eight-
year-old child’s urine for three days.
23. Dr. Cairang Nangjia, a Tibetan scholar and practitioner 
with an independent clinic (previously affiliated to Qinghai 
University’s Tibetan Medical College), informed me that 
at Lhasa Mentsikhang bongnak is currently kept for a day 
in alcohol to which a bit of musk (gla rtsi) is added before 
compounding. At Qinghai’s Provincial Tibetan Hospital 
bongnak is boiled in water beforehand, whereas in some 
private clinics it is added in unprocessed form. Cairang 
Nangjia explained that private doctors who make their 
own medicine know the dose and strength of the bongnak 
they put. In larger institutions this is not the case, hence 
the need to reduce (and standardize) its potency as a safety 
precaution (Personal Communication, December 6, 2017).
24. Blaikie (2014: 286) reports that Garuda 5 is also 
pervasively prescribed in Ladakh, where the detoxification 
of bongnak includes “several hours of constant grinding 
by hand while mixing in precise proportions of a ru ra 
(Terminalia chebula), which neutralizes its poison.” 
25. In Chinese medicine, boiled aconite roots are also 
reported to be tested traditionally through taste: the 
absence of tingling and numbing sensations from trying 
the decoction implies they are ready for use  
(Nyirimigabo et al. 2015: 11).
26. Khyung Nga Nila pills have the same size and color 
as the standard Garuda 5 formula, to which some extra 
components are added to make it more effective against 
sores and skin problems (Dr. Penpa Tsering, Interview, July 
18, 2015). Dr. Pasang Yonten Arya learned about this recipe 
from the famed Dr. Tenzin Chödrak, and remembered 
that detoxified lapis lazuli (mu men, hence ‘nīla’ which 
is Sanskrit for ‘blue’) and refined mercury are added 
(Personal Communication, August 6, 2016). A third Garuda 
formula produced at Men-Tsee-Khang, with a similar 
appearance, is Khyung Nga Chuder Chen. Its indications 
include bone aches, muscular spasm, and shooting pains  
in the limbs.
27. Garuda 5’s beneficial qualities (phan yon) may be 
summarized as follows (translated from Penpa Tsering 
and Choelothar 2013: 7, which is memorized by fourth-
year medical students at Men-Tsee-Khang): “treats 
severe stomach pain, inflammation of the head (including 
ears, nose, and gums), pain due to intestinal parasites 
(srin), tonsillitis, itching and cracking skin, and is 
particularly excellent against leprosy and ‘yellow fluid’ 
(chu ser) disorders. Its potency is neutral, and the mode of 
administration mentioned here is four pills taken together 
with boiled water.” Interestingly, Garuda 5 is listed as a pill 
that cures cold disorders in the Subsequent Tantra (Men-
Tsee-Khang 2011b: 91), whereas pain and inflammation are 
usually associated with excess heat.
28. Dr. Penpa Tsering equally felt that Garuda 5 is 
prescribed much more by Tibetan doctors nowadays, as 
bacterial and viral diseases have become more prevalent 
(Interview, July 18, 2015). See Prost (2008: 43-53) for a list 
and discussion of diseases and disorders prevalent in the 
exile community and their purported causes, and for the 
link with social inequalities between different generations 
of (migration of) Tibetans (ibid: 54-73).
29. Similarly, Dr. Choelothar mentioned that ga bur is 
often taken out of formulations as it is dangerous to 
use for patients suffering from ngyan nad; infectious 
epidemics such as Hepatitis B and Tuberculosis, which are 
locally prevalent in Dharamsala (Barbara Gerke, Personal 
Communication, June 2, 2016).
30. A ru ra, chebulic myrobalan, is generally referred to as 
the king of medicine (sman gyi rgyal po). The superior type 
of a ru, held in the right hand of the Medicine Buddha, is a 
panacea for all bodily ailments. Mercury is equally said to 
be the king of poison. Camphor is the king of medicines in 
the context of hot illness-relieving powders (Chapter 4 of 
the Subsequent Tantra).
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31. For interpretations beyond the conventional poison/
medicine dichotomy of historical Chinese medical texts, 
refer to the foundational work by Paul Unschuld (1975) and 
Obringer’s (1997) analysis and comparison with the Greek 
term pharmakon.
32. See Keller (1999: 44) and Wiesner (2014) for the 
application of the risk/benefit ratio to herbs in the 
European context, and van der Valk (2017: 217-228) for 
how this plays out for the reformulated Garuda 5 produced 
by the Swiss pharmaceutical company PADMA.
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